Immuneel Therapeutics

Collaboration to evaluate AI-led discovery across antibodies, ADCs and gene therapy platforms

At Scale-Up Health, an initiative by Eight Roads Ventures, industry leaders highlighted that the challenge is no longer scientific…

According to GlobalData’s Drugs Database, blood cancers account for over half of all CAR-Ts in the active pipeline* and make up…

Budget provisions focus on customs duty exemptions, R&D funding, and healthcare infrastructure expansion

Amit Mookim, CEO, Immuneel Therapeutics urges the govt to focus on establishing a strong compliance framework and expediting…

Industry leaders share their expectations from the upcoming Union budget 2025-26. Increased allocation for R&D and…

Mookim will focus on establishing partnerships with providers, practitioners, and public health, and delivering current CART…

In this video, Arun Anand, COO, Immuneel Therapeutics and Dr Bruce Levine, of the University of Pennsylvania Perelman School of…

Seventy seven overall responses at day 90 in patients with multi-line treated leukemia and lymphoma who received Varnimcabtagene…

The facility will currently focus on autologous cell therapies including CAR-T cell therapy for lymphomas and leukaemias